Rezolute (RZLTD) Stock Price, News & Analysis

Company Overview

Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company’s research is centered on addressing disorders caused by excessive or dysregulated insulin activity, with the goal of improving glucose control and reducing the burden of serious complications.

Rezolute’s lead product candidate, RZ358, is an investigational monoclonal antibody designed to moderate excessive insulin signaling. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces excessive insulin and can cause dangerously low blood sugar levels. Rezolute has also developed RZ402, an oral plasma kallikrein inhibitor being evaluated for potential use in diabetic macular edema and other vascular complications.

The company was formerly known as AntriaBio, Inc. and adopted the Rezolute name as it shifted its focus toward therapies for metabolic and rare diseases. Rezolute is headquartered in Redwood City, California, and its development activities are directed toward patients in the United States and international markets. Nevan Elam serves as the company’s chief executive officer.

Key Stats

• Today's Range: $3.97 to $4.20
• 50-Day Range: $3.84 to $5.09
• 52-Week Range: $16.00 to $24.05
• Volume: 1.65 million shs
• Average Volume: 4,788 shs
• Market Capitalization: $33.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:RZLTD
• CIK: N/A
• Web: www.rezolutebio.com
• Phone: 650 206 4507
• Fax: N/A
• Employees: 23
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.33 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -153.46%
• Return on Assets: -111.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.26
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.24 per share
• Price / Book: 3.23

Miscellaneous

• Outstanding Shares: 8,418,000
• Free Float: N/A
• Market Cap: $33.76 million
• Optionable: Not Optionable
• Beta: 4.63